Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan

Karaganda Medical University

Status: Completed

Conditions: Vaccine Adverse Reaction; Covid19

Treatments: Biological: Sputnik V

Study type: Observational

Funder types: Other

Identifiers

NCT04871841

128/36-21-23

Details and patient eligibility

About

This study will assess the safety, reactogenicity, and immunogenicity of Gam-COVID-Vac (Sputnik V) vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). The vaccine contains two recombinant adenoviral vectors harbouring SARS-CoV-2 Spike gene. The vaccine will be administered intramuscularly on a 2-dose prime-boost schedule. Participants will be healthy adults aged greater than or equal to 18 years, voluntarily undergoing vaccination according to the guidelines of the Ministry of Healthcare of Kazakhstan.

Full description

Sputnik V (Gam-COVID-Vac) is an adenoviral vector vaccine developed by The Gamaleya Research Institute of Epidemiology and Microbiology (Moscow, Russia), registered and approved by the Ministry of Healthcare of Kazakhstan. The vaccine incorporates two recombinant adenoviral (rAd) vectors, rAd5 and rAd26, harbouring SARS-CoV-2 Spike (S) gene.

Earlier Phase I/II clinical trials established that Sputnik V is safe and efficacious when given intramuscularly in two sequential doses, as a rAd26-S prime at day 0 followed by rAd5-S boost at day 21, at 1x10^11 particles per dose. The aim of the current study is to provide data on the safety, reactogenicity, and immunogenicity of Sputnik V in adults vaccinated in Kazakhstan using the established vaccination regimen. In addition, the effects of prior COVID-19 exposure on the vaccine safety, reactogenicity, and immunogenicity will be assessed.

Enrollment: 82 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participant must be healthy (in the physician's clinical judgment and as confirmed by medical records, and physical examination at screening).
• Willing to give informed consent, and answer short questionnaires on past exposure to COVID-19 and post-vaccination reactogenicity.
• Willing to comply with the requirements of the protocol.

Exclusion criteria

• Participant shows signs of an acute illness (excluding minor illnesses such as diarrhea or mild upper respiratory tract infection).
• Participant has a positive laboratory-confirmed test result for SARS-CoV-2 infection at screening.
• Deemed by investigators to be unlikely to complete study protocol.

Trial design

82 participants in 1 patient group

Sputnik V Vaccinees

Description:

Participants (healthy adults aged \>=18) will receive rAd26-S prime at day 0 and rAd5-S boost at day 21.

Treatment:

Biological: Sputnik V